

# Diana A Gorog

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6838803/publications.pdf>

Version: 2024-02-01

114  
papers

2,748  
citations

186265  
28  
h-index

223800  
46  
g-index

118  
all docs

118  
docs citations

118  
times ranked

3380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 1415-1424.	13.7	223
2	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180
3	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	3.4	149
4	Prognostic Value of Plasma Fibrinolysis Activation Markers in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2701-2709.	2.8	102
5	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (FHRA). <i>Cardiovascular Research</i> , 2021, 117, 2705-2729.	3.8	95
6	Endogenous Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1683-1699.	2.8	93
7	Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. <i>Nature Reviews Cardiology</i> , 2009, 6, 273-282.	13.7	90
8	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. <i>European Heart Journal</i> , 2021, 42, 2265-2269.	2.2	81
9	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	2.2	80
10	Platelet Function Tests in Clinical Cardiology. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2115-2129.	2.8	74
11	Impaired Endogenous Thrombolysis in Acute Coronary Syndrome Patients Predicts Cardiovascular Death and Nonfatal Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2107-2115.	2.8	73
12	Allopurinol as a therapeutic option in cardiovascular disease. , 2017, 172, 139-150.		69
13	Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 595-607.	2.1	65
14	Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. <i>European Heart Journal</i> , 2019, 40, 295-305.	2.2	61
15	Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs—fact or artifact?. <i>Nature Reviews Cardiology</i> , 2009, 6, 365-373.	13.7	54
16	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	2.2	52
17	Use of thrombectomy devices in primary percutaneous coronary intervention: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013, 163, 229-241.	1.7	50
18	Arterial Thrombus Stability. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2036-2047.	2.8	48

#	ARTICLE	IF	CITATIONS
19	First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: Possible relationship to the "Japanese paradox". International Journal of Cardiology, 2011, 152, 43-48.	1.7	47
20	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 221-234.	3.0	43
21	Incidence of thrombotic complications in COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 52, 999-1006.	2.1	42
22	METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectoriSâ€”The METAMORPHOSIS Trial. Thrombosis and Haemostasis, 2018, 118, 2126-2133.	3.4	39
23	Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. European Heart Journal, 2013, 34, 354-363.	2.2	38
24	Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. Thrombosis Research, 2014, 133, 919-926.	1.7	36
25	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1949-1962.	2.8	36
26	Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size. Thrombosis and Haemostasis, 2018, 118, 601-612.	3.4	34
27	Distal Myocardial Protection During Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2005, 46, 1434-1445.	2.8	32
28	Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19. Scientific Reports, 2020, 10, 21379.	3.3	31
29	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 125-140.	3.0	31
30	Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT Scanning. Critical Care Medicine, 2021, 49, 804-815.	0.9	29
31	Antithrombotic therapy in diabetes: which, when, and for how long?. European Heart Journal, 2021, 42, 2235-2259.	2.2	29
32	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. Korean Circulation Journal, 2021, 51, 202.	1.9	27
33	Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?. Journal of the American College of Cardiology, 2019, 74, 1366-1375.	2.8	22
34	Out-of-hospital cardiac arrest: A systematic review of current risk scores to predict survival. American Heart Journal, 2021, 234, 31-41.	2.7	21
35	Platelet Function Tests: Why They Fail to Guide Personalized Antithrombotic Medication. Journal of the American Heart Association, 2015, 4, .	3.7	20
36	Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. Europace, 2019, 21, 1297-1306.	1.7	20

#	ARTICLE	IF	CITATIONS
37	Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. <i>Thrombosis and Haemostasis</i> , 2020, 120, 565-578.	3.4	20
38	PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 423-429.	2.1	18
39	Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19. <i>European Heart Journal</i> , 2020, 41, 3198-3199.	2.2	18
40	Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2017, 117, 457-470.	3.4	17
41	Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 13-21.	2.3	17
42	Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. <i>Platelets</i> , 2016, 27, 687-693.	2.3	16
43	Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1850.	4.1	16
44	Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis. <i>Thrombosis Research</i> , 2019, 173, 102-108.	1.7	16
45	Global Thrombosis Test – a possible monitoring system for the effects and safety of dabigatran. <i>Thrombosis Journal</i> , 2015, 13, 39.	2.1	15
46	“Mind the gap” acute coronary syndrome in women: A contemporary review of current clinical evidence. <i>International Journal of Cardiology</i> , 2017, 227, 840-849.	1.7	15
47	Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2020, 133, 1328-1335.	1.5	15
48	Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1-11.	2.1	15
49	Treatment of calcified coronary artery lesions. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 683-690.	1.5	14
50	Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial. <i>Cardiovascular Research</i> , 2021, 117, 623-634.	3.8	13
51	Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes. <i>Open Heart</i> , 2015, 2, e000258.	2.3	12
52	MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment. <i>European Cardiology Review</i> , 2020, 15, e20.	2.2	12
53	More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy – Current Data and Future Directions. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	11
54	Relationship of Platelet Reactivity and Inflammatory Markers to Recurrent Adverse Events in Patients with ST-Elevation Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1785-1794.	3.4	11

#	ARTICLE	IF	CITATIONS
55	Impact of Preadmission Morphine on Reinfarction in Patients With STâ€Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Metaâ€Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 54-62.	4.7	11
56	Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1472.	4.1	11
57	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	1.7	11
58	2â€Oxothiazolidineâ€4â€carboxylic acid inhibits vascular calcification via induction of glutathione synthesis. <i>Journal of Cellular Physiology</i> , 2021, 236, 2696-2705.	4.1	9
59	Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox. <i>Current Vascular Pharmacology</i> , 2018, 16, 477-483.	1.7	9
60	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 343-355.	1.0	9
61	Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 413-426.	2.1	8
62	Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 392-395.	2.1	8
63	Fatal heart block from intentional yew tree ( <i>Taxus baccata</i> ) ingestion: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-4.	0.6	8
64	Screening for venous thromboembolism in patients with COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 985-991.	2.1	8
65	Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. <i>Journal of Clinical Lipidology</i> , 2019, 13, 788-796.	1.5	7
66	Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 161-162.	1.6	7
67	Endogenous fibrinolysisâ€Relevance to clinical thrombosis risk assessment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13471.	3.4	7
68	Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. <i>Thrombosis and Haemostasis</i> , 2021, , .	3.4	7
69	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020, 27, 661-676.	1.2	7
70	A Cautionary Tale. <i>Journal of Clinical Neuromuscular Disease</i> , 2005, 7, 25-28.	0.7	6
71	Use of bioresorbable vascular scaffold: a meta-analysis of patients with coronary artery disease. <i>Open Heart</i> , 2016, 3, e000462.	2.3	6
72	Potential of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 593-602.	2.1	6

#	ARTICLE	IF	CITATIONS
73	Thrombotic Profile and Oral Anticoagulation in Asian and Non-Asian Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2822-2824.	2.8	6
74	Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 192-198.	2.1	6
75	Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?. <i>Cardiology Journal</i> , 2021, , .	1.2	6
76	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8.	1.7	6
77	The role of distal myocardial protection devices during percutaneous coronary interventions. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 52-59.	0.9	5
78	Usefulness of Platelet Function Tests to Predict Bleeding With Antithrombotic Medications. <i>Cardiology in Review</i> , 2015, 23, 323-327.	1.4	5
79	Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 20-27.	2.0	5
80	Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. <i>European Heart Journal Supplements</i> , 2020, 22, M26-M34.	0.1	5
81	Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2020.	2.4	5
82	Fibrinolysis in Platelet Thrombi. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5135.	4.1	5
83	A rare cause of myocardial infarction with non-obstructive coronary arteries” case report of ST-segment elevation myocardial infarction caused by a mediastinal mass. <i>European Heart Journal - Case Reports</i> , 2018, 2, e008.	0.6	4
84	A case of repetitive myocardial infarction with unobstructed coronaries due to Churg”Strauss syndrome. <i>European Heart Journal - Case Reports</i> , 2019, 3, .	0.6	4
85	Low-grade endotoxaemia and platelets: a deadly aggregation. <i>European Heart Journal</i> , 2020, 41, 3166-3168.	2.2	4
86	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis. <i>American Journal of Cardiology</i> , 2021, 142, 147-151.	1.6	4
87	Novel antithrombotic agents for atrial fibrillation. , 2012, 134, 345-354.		3
88	Endovascular thrombectomy 2020: open issues. <i>European Heart Journal Supplements</i> , 2020, 22, M13-M18.	0.1	3
89	RIC in COVID-19” a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 925-930.	2.6	3
90	When a meta-analysis equals a single large-scale trial with meaningful follow-up. <i>European Heart Journal</i> , 2021, 42, 3884-3885.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?. <i>European Heart Journal</i> , 2021, 42, 3187-3189.	2.2	3
92	Preoperative Atrial Fibrillation is associated with long-term mortality in patients undergoing surgical Aortic valve Replacement. <i>Journal of Cardiac Surgery</i> , 2021, 36, 3561-3566.	0.7	3
93	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. <i>Cardiology Journal</i> , 2021, 28, 607-614.	1.2	3
94	NOAC in Acute Coronary Syndrome and AF?. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2014, 14, 154-164.	0.7	3
95	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021, , .	1.2	3
96	Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3801.	4.3	2
97	Percutaneous coronary intervention with drug-eluting stent versus coronary artery bypass grafting: A meta-analysis of patients with left main coronary artery disease. <i>International Journal of Cardiology</i> , 2017, 249, 101-106.	1.7	2
98	Precision Treatment in ACS – Role of Assessing Fibrinolysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 929.	2.4	2
99	The authors reply. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, e1190-e1191.	0.9	2
100	98 – Assessment of Endogenous Thrombolysis Predicts Cardiovascular Risk in Patient with ST-elevation Myocardial Infarction. <i>Heart</i> , 2016, 102, A69-A70.	2.9	1
101	Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics. <i>Thrombosis and Haemostasis</i> , 2020, 120, 008-010.	3.4	1
102	Spontaneous Reperfusion in Patients with Transient ST-Elevation Myocardial Infarction – Prevalence, Importance and Approaches to Management. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 169-180.	2.6	1
103	Coronary thrombosis: In vivo, ex vivo and in vitro. <i>BMJ Case Reports</i> , 2009, 2009, bcr0920080983-bcr0920080983.	0.5	1
104	Spontaneous Coronary Artery Dissection: The Phantom Menace. <i>Cardiology Research</i> , 2016, 7, 214-217.	1.1	1
105	Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?. <i>Current Vascular Pharmacology</i> , 2018, 16, 427-436.	1.7	1
106	NETs in the infarct-related coronary artery – a marker or mediator of adverse outcome?. <i>Thrombosis and Haemostasis</i> , 2022, , .	3.4	1
107	Rivaroxaban – a safe alternative to warfarin in atrial fibrillation cardioversion. <i>British Journal of Cardiac Nursing</i> , 2015, 10, 41-43.	0.1	0
108	Lowering the risk of stroke prevention: Managing bleeding complications. <i>International Journal of Cardiology</i> , 2019, 274, 351-352.	1.7	0

#	ARTICLE	IF	CITATIONS
109	Thrombosis Risk with Transcatheter Aortic Valve Replacement. Structural Heart, 2020, 4, 349-359.	0.6	0
110	Peripartum cardiomyopathy: can the link between prolactin and PAI-1 provide a clue?. Cardiovascular Research, 2020, 116, 1791-1793.	3.8	0
111	Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?. SN Applied Sciences, 2021, 3, 1.	2.9	0
112	Global Thrombosis Test: Occlusion is attributable to shear-induced platelet thrombus formation.. TH Open, 0, 0, .	1.4	0
113	Global Thrombosis Test: Occlusion Is Attributable to Shear-Induced Platelet Thrombus Formation. TH Open, 2021, 05, e591-e597.	1.4	0
114	Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease. JAMA Cardiology, 0, , .	6.1	0